Roberta Zappasodi

Weill Medical Coll Of Cornell Univ

$1,665,977

Attributed

$1,665,977

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $732.8K · FY2023–25

$1M$750K$500K$250K$0

'23

'24

'25

Funding mix

By agency

NIH$1,665,977 · 1

By mechanism

R01$1,665,977 · 1

Top collaborators

No co-investigators on record.

Most similar at Weill Medical Coll Of Cornell Univ

Same institution · by research overlap

Others in their field

Other Rising Stars on “Activated B Cell Like”

Anil Gupta · Scripps Research Institute, The$7,340,144
Timothy O'Connor · Rockefeller University$7,019,416
Magnus Adrian Gero Hoffmann · California Institute Of Technology$3,559,750
Maria Yazdanbakhsh · Leiden University Medical Center$2,600,040
Saad J. Kenderian · Mayo Clinic Rochester$2,442,317
Jean L Koff · Georgia Institute Of Technology$2,365,235

Research focus

Activated B Cell LikeAccelerationAdultAffectAdaptive Immune SystemAntigen PresentationAntitumor EffectB-Cell Antigen ReceptorB-Cell LymphomasB-Cell Nonhodgkins LymphomaBcl10 GeneBiological HeterogeneityBiological MarkersCell LineCellsCell SurvivalChimeric Antigen Receptor T CellsChronicClassificationClinicClinical DevelopmentClinical InvestigationClinically RelevantClinical Trials

Grant awards (4)

Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy$478,551

R01 · FY2025 · CA · contact PI

MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL$254,250

R01 · FY2025 · CA · contact PI

Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy$454,625

R01 · FY2024 · CA · contact PI

Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy$478,551

R01 · FY2023 · CA · contact PI